🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,867 results for “De” Clear

  1. RITALINE L.P. 10 mg, gélule à libération prolongée

    Tour Hekla

    Attention Deficit Disorder with or without Hyperactivity (ADHD) is a neurodevelopmental disorder characterized by disabling symptoms of inattention and/or hyperactivity-impulsivity beginning before the age of 12 with significant personal, social, academic and/or occupational impact (American Psychiatric Association 2013). This disorder, whose prevalence is around 5% in children and adolescents, affects 2.6% of adults (American Psychiatric Association 2013; Song et al. 2021).

    approved small molecule active

    1 trial

  2. RIVAROXABAN , RIVAROXABAN, RIVAROXABAN

    Pari Pharma GmbH

    Patients with excessive supraventricular ectopies or short atrial runs (ESVEA) defined as ≥ 1% premature atrial contractions (PAC) /24 hours or any atrial runs ≥ 20 PACs (but shorter than 30 seconds) on a 24-hour Holter ECG monitoring and CHA2DS2VASC score ≥ 3. Patients with any atrial runs ≥ 20 PACs but shorter than 30 seconds on a 15-21 days Holter ECG monitoring and CHA2DS2VASC score ≥ 3 may also be included in the Short-Run trial.

    approved small molecule active

    1 trial

  3. RIVASTIGMINE, Rivastigmin adhesive plaster 9.5 mg placebo containing 0 mg of rivastigmin, Rivastigmin adhesive plaster 4.6 mg placebo containing 0 mg of rivastigmin, RIVASTIGMINE

    Disc Medicine

    Depression

    approved small molecule active

    1 trial

  4. RIXUBIS: On-Demand

    Takeda

    Hemophilia B

    approved mab completed

    1 trial

  5. RO7034067, Evrysdi 0.75 mg/mL powder for oral solution

    Hoffmann-La Roche

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  6. ROPIVACAINE , SODIUM CHLORIDE

    Disc Medicine

    Urolithiasis

    approved small molecule active

    1 trial

  7. Rabbit ATG, (Genzyme)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Aplastic Anemia

    approved small molecule active

    1 trial

  8. Rabipur Pulver und Lösungsmittel zur Herstellung einer Injektionslösung in einer Fertigspritze Tollwut-Impfstoff (inaktiviert), RABIPUR, poudre et solvant pour solution injectable en seringue préremplie. Vaccin rabique (inactivé)., Rabipur poeder en oplosmiddel voor oplossing voor injectie in een voorgevulde spuit.Rabiësvaccin (geïnactiveerd).

    The George Institute

    rabies pre-exposure prophylaxis

    approved small molecule active

    1 trial

  9. Raltegravir

    Merck KGaA, Darmstadt, Germany

    Human Immunodeficiency Virus (HIV) Infection

    approved small molecule completed

    1 trial

  10. Ramelteon

    Takeda

    Seasonal Affective Disorder

    approved small molecule completed

    1 trial

  11. Ramelteon

    Takeda

    Bipolar Disorder

    approved small molecule terminated

    2 trials

  12. Ramelteon and zolpidem

    Takeda

    Chronic Insomnia

    approved small molecule completed

    1 trial

  13. Ramelteon, zolpidem and placebo

    Takeda

    Insomnia

    approved small molecule completed

    1 trial

  14. Rasagiline

    Teva Pharma GmbH

    Depressive Symptoms

    approved small molecule completed

    1 trial

  15. Rebamipide

    Otsuka Beijing Research Institute

    Stomach Ulcer

    approved small molecule completed

    1 trial

  16. Rebamipide 2% ophthalmic solution

    Samsung Bioepis NL B.V.

    Dry Eye Disease (DED)

    approved small molecule active

    1 trial

  17. Recombinant Human Adenovirus Type 5 injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    approved small molecule active

    1 trial

  18. Recombinant human growth hormone

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Achondroplasia

    approved small molecule active

    1 trial

  19. Recombinant human growth hormone (r-hGH)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Dwarfism, Pituitary

    approved small molecule completed

    1 trial

  20. Recombinant tissue plasminogen activator (rt-PA)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pulmonary Thromboembolisms

    approved small molecule active

    1 trial

  21. Regadenoson

    Aspire Biopharma Holdings

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  22. Regimen:TDF+3TC+EFV

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hiv

    approved small molecule completed

    1 trial

  23. Regimen：BIC+FTC+TAF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV Infection

    approved small molecule active

    1 trial

  24. Rematazolam Besylate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Emergence Agitation

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources